Posts

Managing Urinary Symptoms During Advanced Prostate Cancer Treatment:

Image
What Patients Need to Know BLUF (Bottom Line Up Front): Urinary problems including frequent nighttime urination (nocturia), urgency, weak stream, and incomplete bladder emptying are common but often undertreated side effects of prostate cancer therapies, particularly androgen deprivation therapy (ADT) and advanced antiandrogen drugs. While many oncologists and urologists focus primarily on cancer control, multiple evidence-based treatments and practical strategies can significantly improve quality of life and sleep for patients experiencing these debilitating symptoms. The Hidden Burden of Treatment-Related Urinary Dysfunction For men undergoing treatment for advanced prostate cancer, the disease itself often takes a back seat to the daily challenges of managing urinary symptoms. While much attention focuses on well-known side effects like hot flashes, fatigue, and sexual dysfunction, urinary problems frequently emerge as among the most disruptive to quality of life—yet they often...
Post a Comment
Read more

'Most Compelling' Data Yet for Metastasis-Directed Therapy in Prostate Cancer | MedPage Today

Image
'Most Compelling' Data Yet for Metastasis-Directed Therapy in Prostate Cancer | MedPage Today Metastasis-Directed Therapy Shows Promise for Oligometastatic Prostate Cancer BLUF (Bottom Line Up Front): A major new meta-analysis of six randomized trials provides the strongest evidence yet that metastasis-directed therapy (MDT)—using targeted radiation or surgery to treat a limited number of cancer metastases—significantly delays disease progression in men with oligometastatic prostate cancer. While the treatment improved multiple important survival measures, the improvement in overall survival narrowly missed statistical significance. This approach represents a potential paradigm shift for patients with limited metastatic spread, though experts note that modern PSMA-PET imaging may further improve patient selection for this strategy. Understanding Oligometastatic Disease Oligometastatic prostate cancer represents an intermediate state between localized disease and widespread ...
Post a Comment
Read more

Practical Solutions to Family Fear of Invisible Radiation from Pluvicto:

Image
  RadioCode 102 on Amazon $249 Consumer Radiation Detectors to Prove Safety to Your Family BLUF (Bottom Line Up Front) Men taking Pluvicto have experienced unfounded and excessive concern and isolation from their family over radiation hazard. Objective measurement will convince your family far more effectively than scientific papers. Several consumer-grade radiation detectors ($100-400) can measure radiation from Lu-177 Pluvicto and demonstrate in real-time that you're emitting nothing above background levels after 7-10 days. This article provides specific product recommendations, validation data on their accuracy for Lu-177 detection, practical usage protocols, and exactly how to present the data to your family to end the unnecessary month-long isolation. Why Measurement Will Work When Evidence Hasn't W. Edwards Deming was absolutely right. Your family doesn't need more papers and general guidelines —they need concrete, visible proof. Let's make that happen. The P...
Post a Comment
Read more

Single Midlife PSA Test May Predict 20-Year Prostate Cancer Risk:

Image
Single Midlife PSA Test May Identity Long-Term Prostate Cancer Risk | MedPage Today New Evidence Supports Risk-Stratified Screening BLUF (Bottom Line Up Front): A major German study published February 3, 2026, found that men with a PSA below 1.0 ng/mL at midlife face very low prostate cancer risk for the next 20 years—just 3.3% cumulative incidence—suggesting these men could safely reduce screening frequency and avoid unnecessary biopsies. Combined with 23-year follow-up data from Europe's largest screening trial showing a 13% mortality reduction, new FDA-approved blood tests, and updated guidelines for high-risk populations including Black men, the evidence increasingly supports personalized, risk-based screening strategies that maximize early detection benefits while minimizing overdiagnosis harms. A Breakthrough in Risk Stratification For decades, prostate cancer screening has been caught in a dilemma: PSA testing saves lives by detecting cancer early, but it also leads to...
Post a Comment
Read more

Revolutionary Approach: Skipping Biopsy after PSMA PET/CT for Prostate Cancer Surgery Shows Promise

Image
Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI | Prostate Cancer and Prostatic Diseases BLUF (Bottom Line Up Front) Chinese researchers have successfully performed prostate cancer surgery on 120 men without prior biopsy, using advanced imaging alone to diagnose cancer. Published January 31, 2026, in Prostate Cancer and Prostatic Diseases , this study achieved 100% accuracy in detecting clinically significant cancer using a careful algorithm combining PSMA PET/CT and multiparametric MRI scans. While this radical departure from standard practice shows promise for carefully selected patients, it remains experimental and requires independent validation before becoming routine care. The Traditional Path—And Its Problems For decades, prostate biopsy has been the gold standard for diagnosing prostate cancer. A urologist inserts a needle through the rectal wall 10-12 times to collect tissue samples, guided by ultrasound. The procedu...
Post a Comment
Read more